Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome

World Journal of Gastroenterology

Volumn 22, Issue 39, 2016, Pages 8698-8719

  Kaska, Lukasz ^a   Sledzinski, Tomasz ^a   Chomiczewska, Agnieszka ^a   Dettlaff Pokora, Agnieszka ^a   Swierczynski, Julian ^a,b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b State Higher Vocational School in Koszalin   (Poland)

Author keywords

Bariatric surgery; Bile acids; Gut microbiota; Roux en Y gastric bypasses; RXR; TGR 5; Type 2 diabetes

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; GLYCOLITHOCHOLIC ACID; GLYCOURSODEOXYCHOLIC ACID; HYODEOXYCHOLIC ACID; INCRETIN; INSULIN; LITHOCHOLIC ACID; TAKEDA G PROTEIN RECEPTOR 5; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROHYODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GPBAR1 PROTEIN, HUMAN; OXYGEN; PEPTIDE;

BARIATRIC SURGERY; BILE ACID SYNTHESIS; CALORIC RESTRICTION; GASTRIC BANDING; GASTRIC BYPASS SURGERY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; INSULIN SENSITIVITY; INTESTINE FLORA; LAPAROSCOPIC SURGERY; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REMISSION; REVIEW; SLEEVE GASTRECTOMY; WEIGHT REDUCTION; CHEMISTRY; GASTROINTESTINAL TRACT; LIVER; METABOLISM; PATHOLOGY; PROCEDURES;

BARIATRIC SURGERY; BILE ACIDS AND SALTS; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; GASTRIC BYPASS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GLUCOSE; HUMANS; LIVER; OXYGEN; PEPTIDES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; REMISSION INDUCTION;

EID: 84992571541     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i39.8698     Document Type: Review

References (170)

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van d, V, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-781 [PMID: 24880830 DOI: 10.1016/S0140-6736(14)60460-8]
2. Kaska L, Mika A, Stepnowski P, Proczko M, Ratnicki-Sklucki K, Sledzinski T, Goyke E, Swierczynski J. The relationship between specific Fatty acids of serum lipids and serum high sensitivity C-reactive protein levels in morbidly obese women. Cell Physiol Biochem 2014; 34: 1101-1108 [PMID: 25228402 DOI: 10.1159/000366324]
3. Sledzinski T, Sledzinski M, Smolenski RT, Swierczynski J. Increased serum nitric oxide concentration after bariatric surgery-A potential mechanism for cardiovascular benefit. Obes Surg 2010; 20: 204-210 [PMID: 19997784 DOI: 10.1007/s11695-009-0041-2]
4. Swierczynski J, Sledzinski T, Slominska E, Smolenski R, Sledzinski Z. Serum phenylalanine concentration as a marker of liver function in obese patients before and after bariatric surgery. Obes Surg 2009; 19: 883-889 [PMID: 18431611 DOI: 10.1007/s11695-008-9521-z]
5. Swierczynski J, Sledzinski T. The Role of Adipokines and Gastrointestinal Tract Hormones in Obesity. In. Karcz K, Thomusch O, editors. Principles of metabolic surgery: Springer, 2012
6. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]
7. Rial SA, Karelis AD, Bergeron KF, Mounier C. Gut Microbiota and Metabolic Health: The Potential Beneficial Effects of a Medium Chain Triglyceride Diet in Obese Individuals. Nutrients 2016; 8: pii: E281 [PMID: 27187452 DOI: 10.3390/nu8050281]
8. Mutch DM, Clément K. Unraveling the genetics of human obesity. PLoS Genet 2006; 2: e188 [PMID: 17196040 DOI: 10.1371/journal.pgen.0020188]
9. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585 [PMID: 22449317 DOI: 10.1056/NEJMoa1200111]
10. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576 [PMID: 22449319 DOI: 10.1056/NEJMoa1200225]
11. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016; 39: 861-877 [PMID: 27222544 DOI: 10.2337/dc16-0236]
12. Kmietowicz Z. Surgery for obese people with diabetes could save the NHS £100 000 a patient, finds study. BMJ 2016; 353: i3150 [PMID: 27268789]
13. Quercia I, Dutia R, Kotler DP, Belsley S, Laferrère B. Gastrointestinal changes after bariatric surgery. Diabetes Metab 2014; 40: 87-94 [PMID: 24359701 DOI: 10.1016/j.diabet.2013.11.003]
14. Sweeney TE, Morton JM. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. Best Pract Res Clin Gastroenterol 2014; 28: 727-740 [PMID: 25194186 DOI: 10.1016/j.bpg.2014.07.016]
15. Schmidt JB, Pedersen SD, Gregersen NT, Vestergaard L, Nielsen MS, Ritz C, Madsbad S, Worm D, Hansen DL, Clausen TR, Rehfeld JF, Astrup A, Holst JJ, Sjödin A. Effects of RYGB on energy expenditure, appetite and glycaemic control: A randomized controlled clinical trial. Int J Obes (Lond) 2016; 40: 281-290 [PMID: 26303352 DOI: 10.1038/ijo.2015.162]
16. Penney NC, Kinross J, Newton RC, Purkayastha S. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: A systematic review. Int J Obes (Lond) 2015; 39: 1565-1574 [PMID: 26081915 DOI: 10.1038/ijo.2015.115]
17. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, Rizkalla S, Clément K. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049-3057 [PMID: 20876719 DOI: 10.2337/db10-0253]
18. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, Bloom SR, Darzi A, Athanasiou T, Marchesi JR, Nicholson JK, Holmes E. Metabolic surgery profoundly influences gut microbialhost metabolic cross-talk. Gut 2011; 60: 1214-1223 [PMID: 21572120 DOI: 10.1136/gut.2010.234708]
19. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509: 183-188 [PMID: 24670636 DOI: 10.1038/nature13135]
20. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009; 106: 2365-2370 [PMID: 19164560 DOI: 10.1073/pnas.0812600106]
21. Fiorucci S, Distrutti E. Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends Mol Med 2015; 21: 702-714 [PMID: 26481828 DOI: 10.1016/j.molmed.2015.09.001]
22. Nosso G, Griffo E, Cotugno M, Saldalamacchia G, Lupoli R, Pacini G, Riccardi G, Angrisani L, Capaldo B. Comparative Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Glucose Homeostasis and Incretin Hormones in Obese Type 2 Diabetic Patients: A One-Year Prospective Study. Horm Metab Res 2016; 48: 312-317 [PMID: 26788926 DOI: 10.1055/s-0041-111505]
23. Werling M, Vincent RP, Cross GF, Marschall HU, Fändriks L, Lönroth H, Taylor DR, Alaghband-Zadeh J, Olbers T, Le Roux CW. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 2013; 48: 1257-1264 [PMID: 24044585 DOI: 10.3109/00365521.2 013.833647]
24. Luo P, Yu H, Zhao X, Bao Y, Hong CS, Zhang P, Tu Y, Yin P, Gao P, Wei L, Zhuang Z, Jia W, Xu G. Metabolomics Study of Rouxen-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry. J Proteome Res 2016; 15: 1288-1299 [PMID: 26889720 DOI: 10.1021/acs.jproteome.6b00022]
25. Yu H, Ni Y, Bao Y, Zhang P, Zhao A, Chen T, Xie G, Tu Y, Zhang L, Su M, Wei L, Jia W, Jia W. Chenodeoxycholic Acid as a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese Patients. J Clin Endocrinol Metab 2015; 100: 4222-4230 [PMID: 26425885 DOI: 10.1210/jc.2015-2884]
26. Cole AJ, Teigen LM, Jahansouz C, Earthman CP, Sibley SD. The Influence of Bariatric Surgery on Serum Bile Acids in Humans and Potential Metabolic and Hormonal Implications: A Systematic Review. Curr Obes Rep 2015; 4: 441-450 [PMID: 26335653 DOI: 10.1007/s13679-015-0171-x]
27. Argyropoulos G. Bariatric surgery: prevalence, predictors, and mechanisms of diabetes remission. Curr Diab Rep 2015; 15: 15 [PMID: 25702097 DOI: 10.1007/s11892-015-0590-9]
28. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013; 98: E708-E712 [PMID: 23457410 DOI: 10.1210/jc.2012-3736]
29. Haluzíková D, Lacinová Z, Kaválková P, Drápalová J, Křížová J, Bártlová M, Mráz M, Petr T, Vítek L, Kasalický M, Haluzík M. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) 2013; 21: 1335-1342 [PMID: 23670968 DOI: 10.1002/oby.20208]
30. Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet 2012; 379: 2300-2311 [PMID: 22683132 DOI: 10.1016/S0140-6736(12)60401-2]
31. Jahansouz C, Xu H, Hertzel AV, Serrot FJ, Kvalheim N, Cole A, Abraham A, Luthra G, Ewing K, Leslie DB, Bernlohr DA, Ikramuddin S. Bile Acids Increase Independently From Hypocaloric Restriction After Bariatric Surgery. Ann Surg 2015; Epub ahead of print [PMID: 26655924 DOI: 10.1097/SLA.0000000000001552]
32. Dutia R, Embrey M, O'Brien CS, Haeusler RA, Agénor KK, Homel P, McGinty J, Vincent RP, Alaghband-Zadeh J, Staels B, le Roux CW, Yu J, Laferrère B. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond) 2015; 39: 806-813 [PMID: 25599611 DOI: 10.1038/ijo.2015.1]
33. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acidactivated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 2010; 49: 171-185 [PMID: 19932133 DOI: 10.1016/j.plipres.2009.11.001]
34. Kuipers F, Groen AK. FXR: The key to benefits in bariatric surgery? Nat Med 2014; 20: 337-338 [PMID: 24710375 DOI: 10.1038/nm.3525]
35. Zhang F, Yu L, Lin X, Cheng P, He L, Li X, Lu X, Tan Y, Yang H, Cai L, Zhang C. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Mol Endocrinol 2015; 29: 1400-1413 [PMID: 26308386 DOI: 10.1210/me.2015-1155]
36. Spinelli V, Lalloyer F, Baud G, Osto E, Kouach M, Daoudi M, Vallez E, Raverdy V, Goossens JF, Descat A, Doytcheva P, Hubert T, Lutz TA, Lestavel S, Staels B, Pattou F, Tailleux A. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: A comparative study between rats, pigs and humans. Int J Obes (Lond) 2016; 40: 1260-1267 [PMID: 27089995 DOI: 10.1038/ijo.2016.46]
37. Raghow R. Ménage-à-trois of bariatric surgery, bile acids and the gut microbiome. World J Diabetes 2015; 6: 367-370 [PMID: 25897347 DOI: 10.4239/wjd.v6.i3.367]
38. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489 [PMID: 16400329 DOI: 10.1038/nature04330]
39. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, Mioskowski C, Auwerx J, Saladin R. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 2007; 362: 793-798 [PMID: 17825251 DOI: 10.1016/j.bbrc.2007.06.130]
40. Christou NV. Impact of obesity and bariatric surgery on survival. World J Surg 2009; 33: 2022-2027 [PMID: 19440652 DOI: 10.1007/s00268-009-0050-2]
41. Clinical Guidelines-Recommendations of International Diabetes Federation, Chapter 06 Glucose Control Levels. Available from: URL: https://www.idf.org/sites/default/files/IDF T2DM Guideline. pdf
42. Cho YM. A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery. Diabetes Metab J 2014; 38: 406-415 [PMID: 25541603 DOI: 10.4093/dmj.2014.38.6.406]
43. Rhee NA, Vilsbøll T, Knop FK. Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. Diabetes Obes Metab 2012; 14: 291-298 [PMID: 21951387 DOI: 10.1111/j.1463-1326.2011.01505.x]
44. Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep 2014; 14: 482 [PMID: 24623198 DOI: 10.1007/s11892-014-0482-4]
45. Docherty NG, le Roux CW. Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease. Exp Physiol 2014; 99: 1146-1153 [PMID: 25085842 DOI: 10.1113/expphysiol.2014.078790]
46. Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009; 33 Suppl 1: S33-S40 [PMID: 19363506 DOI: 10.1038/ijo.2009.15]
47. Kaska L, Proczko M, Wiśniewski P, Stankiewicz M, Gill D, Sledziński Z. A prospective evaluation of the influence of three bariatric procedures on insulin resistance improvement. Should the extent of undiluted bile transit be considered a key postoperative factor altering glucose metabolism? Wideochir Inne Tech Maloinwazyjne 2015; 10: 213-228 [PMID: 26240621 DOI: 10.5114/wiitm.2015.52062]
48. Faria G, Preto J, da Costa EL, GuimarǍes JT, Calhau C, Taveira-Gomes A. Acute improvement in insulin resistance after laparoscopic Roux-en-Y gastric bypass: is 3 days enough to correct insulin metabolism? Obes Surg 2013; 23: 103-110 [PMID: 23114971 DOI: 10.1007/s11695-012-0803-0]
49. Gómez-Abril S, Morillas-Ariño C, Ponce-Marco JL, Torres-Sánchez T, Delgado-Gomis F, Hernández-Mijares A, Rocha M. Short-and Long-Term Effects of Weight Loss on the Complement Component C3 After Laparoscopic Gastric Bypass in Obese Patients. Obes Surg 2016; Epub ahead of print [PMID: 27143095 DOI: 10.1007/s11695-016-2195-z]
50. Severino A, Castagneto-Gissey L, Raffaelli M, Gastaldelli A, Capristo E, Iaconelli A, Guidone C, Callari C, Bellantone R, Mingrone G. Early effect of Roux-en-Y gastric bypass on insulin sensitivity and signaling. Surg Obes Relat Dis 2016; 12: 42-47 [PMID: 26483070 DOI: 10.1016/j.soard.2015.06.005]
51. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab 2009; 35: 518-523 [PMID: 20152737 DOI: 10.1016/S1262-3636(09)73459-7]
52. Robert M, Belanger P, Hould FS, Marceau S, Tchernof A, Biertho L. Should metabolic surgery be offered in morbidly obese patients with type I diabetes? Surg Obes Relat Dis 2015; 11: 798-805 [PMID: 25868828 DOI: 10.1016/j.soard.2014.12.016]
53. Garciacaballero M, Martínez-Moreno JM, Toval JA, Miralles F, Mínguez A, Osorio D, Mata JM, Reyes-Ortiz A. Improvement of C peptide zero BMI 24-34 diabetic patients after tailored one anastomosis gastric bypass (BAGUA). Nutr Hosp 2013; 28 Suppl 2: 35-46 [PMID: 23834045 DOI: 10.3305/nh.2013.28.sup2.6712]
54. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66: 948-983 [PMID: 25073467 DOI: 10.1124/pr.113.008201]
55. Li T, Chiang JY. Bile acids as metabolic regulators. Curr Opin Gastroenterol 2015; 31: 159-165 [PMID: 25584736 DOI: 10.1097/MOG.0000000000000156]
56. de Aguiar Vallim TQ, Tarling EJ, Ahn H, Hagey LR, Romanoski CE, Lee RG, Graham MJ, Motohashi H, Yamamoto M, Edwards PA. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab 2015; 21: 298-310 [PMID: 25651182 DOI: 10.1016/j.cmet.2015.01.007]
57. Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med 2007; 7: 199-218 [PMID: 17346171]
58. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009; 50 Suppl: S120-S125 [PMID: 18815433 DOI: 10.1194/jlr.R800026-JLR200]
59. Norlin M, Toll A, Björkhem I, Wikvall K. 24-hydroxycholesterol is a substrate for hepatic cholesterol 7alpha-hydroxylase (CYP7A). J Lipid Res 2000; 41: 1629-1639 [PMID: 11013305]
60. Sagar NM, Cree IA, Covington JA, Arasaradnam RP. The interplay of the gut microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract 2015; 2015: 398585 [PMID: 25821460 DOI: 10.1155/2015/398585]
61. Camilleri M, Gores GJ. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol 2015; 309: G209-G215 [PMID: 26138466 DOI: 10.1152/ajpgi.00121.2015]
62. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365 [PMID: 10334992]
63. Grober J, Zaghini I, Fujii H, Jones SA, Kliewer SA, Willson TM, Ono T, Besnard P. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 1999; 274: 29749-29754 [PMID: 10514450]
64. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013; 368: 17-29 [PMID: 22609541 DOI: 10.1016/j.mce.2012.05.004]
65. Ferrannini E, Camastra S, Astiarraga B, Nannipieri M, Castro-Perez J, Xie D, Wang L, Chakravarthy M, Haeusler RA. Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. Diabetes 2015; 64: 3377-3385 [PMID: 26015549 DOI: 10.2337/db15-0214]
66. Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56: 1085-1099 [PMID: 25210150 DOI: 10.1194/jlr.R054114]
67. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966 [PMID: 19346330 DOI: 10.1194/jlr.R900010-JLR200]
68. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-259 [PMID: 16299351 DOI: 10.1194/jlr.R500013-JLR200]
69. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 2013; 6: 295-308 [PMID: 23814609 DOI: 10.1177/1756283X13482996]
70. Chow J, Lee SM, Shen Y, Khosravi A, Mazmanian SK. Hostbacterial symbiosis in health and disease. Adv Immunol 2010; 107: 243-274 [PMID: 21034976 DOI: 10.1016/B978-0-12-381300-8.00 008-3]
71. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, Weir TL, Ehrentraut SF, Pickel C, Kuhn KA, Lanis JM, Nguyen V, Taylor CT, Colgan SP. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe 2015; 17: 662-671 [PMID: 25865369 DOI: 10.1016/j.chom.2015.03.005]
72. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: A gut microbiota perspective. Curr Opin Biotechnol 2013; 24: 160-168 [PMID: 22940212 DOI: 10.1016/j.copbio.2012.08.005]
73. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484 [PMID: 19043404 DOI: 10.1038/nature07540]
74. Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther 2016; 43: 1142-1153 [PMID: 27086647 DOI: 10.1111/apt.13616]
75. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30: 332-338 [PMID: 24625896 DOI: 10.1097/MOG.0000000000000057]
76. Hagey LR, Krasowski MD. Microbial biotransformations of bile acids as detected by electrospray mass spectrometry. Adv Nutr 2013; 4: 29-35 [PMID: 23319120 DOI: 10.3945/an.112.003061]
77. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29: 625-651 [PMID: 16102595 DOI: 10.1016/j.femsre.2004.09.003]
78. Bortolini O, Medici A, Poli S. Biotransformations on steroid nucleus of bile acids. Steroids 1997; 62: 564-577 [PMID: 9292932]
79. Chikai T, Nakao H, Uchida K. Deconjugation of bile acids by human intestinal bacteria implanted in germ-free rats. Lipids 1987; 22: 669-671 [PMID: 3312906]
80. Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V, Gassull MA. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003; 37: 551-557 [PMID: 12601352 DOI: 10.1053/jhep.2003.50116]
81. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103: 3920-3925 [PMID: 16473946 DOI: 10.1073/pnas.0509592103]
82. Philipp B. Bacterial degradation of bile salts. Appl Microbiol Biotechnol 2011; 89: 903-915 [PMID: 21088832 DOI: 10.1007/s00253-010-2998-0]
83. Merritt ME, Donaldson JR. Effect of bile salts on the DNA and membrane integrity of enteric bacteria. J Med Microbiol 2009; 58: 1533-1541 [PMID: 19762477 DOI: 10.1099/jmm.0.014092-0]
84. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141: 1773-1781 [PMID: 21839040 DOI: 10.1053/j.gastro.2011.07.046]
85. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54: 2325-2340 [PMID: 23821742 DOI: 10.1194/jlr. R036012]
86. Hur KY, Lee MS. Gut Microbiota and Metabolic Disorders. Diabetes Metab J 2015; 39: 198-203 [PMID: 26124989 DOI: 10.4093/dmj.2015.39.3.198]
87. Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20: 16452-16463 [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452]
88. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075 [PMID: 16033867 DOI: 10.1073/pnas.0504978102]
89. Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr 2011; 31: 15-31 [PMID: 21568707 DOI: 10.1146/annurev-nutr-072610-145146]
90. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]
91. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723 [PMID: 15505215 DOI: 10.1073/pnas.0407076101]
92. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341: 1241214 [PMID: 24009397 DOI: 10.1126/science.1241214]
93. Caricilli AM, Saad MJ. Gut microbiota composition and its effects on obesity and insulin resistance. Curr Opin Clin Nutr Metab Care 2014; 17: 312-318 [PMID: 24848531 DOI: 10.1097/MCO.0000000000000067]
94. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19: 338-348 [PMID: 23452163 DOI: 10.1111/1469-0691.12140]
95. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103 [PMID: 23719380 DOI: 10.1038/nature12198]
96. Han JL, Lin HL. Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. World J Gastroenterol 2014; 20: 17737-17745 [PMID: 25548472 DOI: 10.3748/wjg.v20.i47.17737]
97. Parks BW, Nam E, Org E, Kostem E, Norheim F, Hui ST, Pan C, Civelek M, Rau CD, Bennett BJ, Mehrabian M, Ursell LK, He A, Castellani LW, Zinker B, Kirby M, Drake TA, Drevon CA, Knight R, Gargalovic P, Kirchgessner T, Eskin E, Lusis AJ. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab 2013; 17: 141-152 [PMID: 23312289 DOI: 10.1016/j.cmet.2012.12.007]
98. Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2013; 13: 514-522 [PMID: 23032991 DOI: 10.1038/tpj.2012.43]
99. Liou AP, Paziuk M, Luevano JM, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013; 5: 178ra41 [PMID: 23536013 DOI: 10.1126/scitranslmed.3005687]
100. Kong LC, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL, Zucker JD, Doré J, Clément K. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013; 98: 16-24 [PMID: 23719559 DOI: 10.3945/ajcn.113.058743]
101. Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol 2012; 9: 590-598 [PMID: 22926153 DOI: 10.1038/nrgastro.2012.161]
102. Aron-Wisnewsky J, Clement K. The effects of gastrointestinal surgery on gut microbiota: potential contribution to improved insulin sensitivity. Curr Atheroscler Rep 2014; 16: 454 [PMID: 25214424 DOI: 10.1007/s11883-014-0454-9]
103. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1671-1677 [PMID: 19360006 DOI: 10.1038/oby.2009.102]
104. Myronovych A, Kirby M, Ryan KK, Zhang W, Jha P, Setchell KD, Dexheimer PJ, Aronow B, Seeley RJ, Kohli R. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring) 2014; 22: 390-400 [PMID: 23804416 DOI: 10.1002/oby.20548]
105. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenomewide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60 [PMID: 23023125 DOI: 10.1038/nature11450]
106. Kaji I, Karaki S, Kuwahara A. Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 2014; 89: 31-36 [PMID: 24458110 DOI: 10.1159/000356211]
107. Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, Petersen KF, Kibbey RG, Goodman AL, Shulman GI. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 2016; 534: 213-217 [PMID: 27279214 DOI: 10.1038/nature18309]
108. Vítek L, Haluzík M. The role of bile acids in metabolic regulation. J Endocrinol 2016; 228: R85-R96 [PMID: 26733603 DOI: 10.1530/JOE-15-0469]
109. Barrasa JI, Olmo N, Lizarbe MA, Turnay J. Bile acids in the colon, from healthy to cytotoxic molecules. Toxicol In Vitro 2013; 27: 964-977 [PMID: 23274766 DOI: 10.1016/j.tiv.2012.12.020]
110. Scherer M, Gnewuch C, Schmitz G, Liebisch G. Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3920-3925 [PMID: 19819765 DOI: 10.1016/j.jchromb.2009.09.038]
111. Yamamoto R, Tazuma S, Kanno K, Igarashi Y, Inui K, Ohara H, Tsuyuguchi T, Ryozawa S. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: A randomized trial. J Hepatobiliary Pancreat Sci 2016; 23: 132-136 [PMID: 26705893 DOI: 10.1002/jhbp.316]
112. Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: A meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2014; 12: 1090-1100.e2; quiz e61 [PMID: 24321208 DOI: 10.1016/j.cgh.2013.11.031]
113. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A populationbased cohort study. Hepatology 2007; 46: 1131-1137 [PMID: 17685473 DOI: 10.1002/hep.21795]
114. Adams LB, Chang C, Pope J, Kim Y, Liu P, Yates A. Randomized, Prospective Comparison of Ursodeoxycholic Acid for the Prevention of Gallstones after Sleeve Gastrectomy. Obes Surg 2016; 26: 990-994 [PMID: 26342481 DOI: 10.1007/s11695-015-1858-5]
115. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7: 2811-2818 [PMID: 26668692 DOI: 10.4254/wjh.v7.i28.2811]
116. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313-1316 [PMID: 12016314 DOI: 10.1126/science.1070477]
117. Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci 2012; 33: 552-558 [PMID: 22889594 DOI: 10.1016/j.tips.2012.07.003]
118. Gao J, He J, Zhai Y, Wada T, Xie W. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009; 284: 25984-25992 [PMID: 19617349 DOI: 10.1074/jbc.M109.016808]
119. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res 2009; 50: 1509-1520 [PMID: 19346331 DOI: 10.1194/jlr.R900007-JLR200]
120. Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int 2003; 23: 315-322 [PMID: 14708891]
121. Keitel V, Kubitz R, Häussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol 2008; 14: 5620-5629 [PMID: 18837077 DOI: 10.3748/wjg.14.5620]
122. Han SI, Studer E, Gupta S, Fang Y, Qiao L, Li W, Grant S, Hylemon PB, Dent P. Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes. Hepatology 2004; 39: 456-463 [PMID: 14767998 DOI: 10.1002/hep.20043]
123. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acidactivated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009; 30: 570-580 [PMID: 19758712 DOI: 10.1016/j.tips.2009.08.001]
124. Rometo D, Korytkowski M. Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery. Curr Diab Rep 2016; 16: 23 [PMID: 26879306 DOI: 10.1007/s11892-016-0718-6]
125. Schittenhelm B, Wagner R, Kähny V, Peter A, Krippeit-Drews P, Düfer M, Drews G. Role of FXR in β-cells of lean and obese mice. Endocrinology 2015; 156: 1263-1271 [PMID: 25599407 DOI: 10.1210/en.2014-1751]
126. Ding L, Pang S, Sun Y, Tian Y, Yu L, Dang N. Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. Int J Endocrinol 2014; 2014: 751859 [PMID: 24872814 DOI: 10.1155/2014/751859]
127. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids 2014; 86: 62-68 [PMID: 24819989 DOI: 10.1016/j.steroids.2014.04.016]
128. Dossa AY, Escobar O, Golden J, Frey MR, Ford HR, Gayer CP. Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. Am J Physiol Gastrointest Liver Physiol 2016; 310: G81-G92 [PMID: 26608185 DOI: 10.1152/ajpgi.00065.2015]
129. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-719 [PMID: 12419312]
130. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D, Murgolo NJ, Keane K, Davis HR, Hedrick J, Gustafson EL. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 2006; 398: 423-430 [PMID: 16724960 DOI: 10.1042/BJ20060537]
131. Vettorazzi JF, Ribeiro RA, Borck PC, Branco RC, Soriano S, Merino B, Boschero AC, Nadal A, Quesada I, Carneiro EM. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism 2016; 65: 54-63 [PMID: 26892516 DOI: 10.1016/j.metabol.2015.10.021]
132. Keitel V, Görg B, Bidmon HJ, Zemtsova I, Spomer L, Zilles K, Häussinger D. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010; 58: 1794-1805 [PMID: 20665558 DOI: 10.1002/glia.21049]
133. Stepanov V, Stankov K, Mikov M. The bile acid membrane receptor TGR5: A novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res 2013; 33: 213-223 [PMID: 23782454 DOI: 10.3109/10799893 .2013.802805]
134. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acidstimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012; 165: 414-423 [PMID: 21718300 DOI: 10.1111/j.1476-5381.2011.01561.x]
135. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439 [PMID: 17928588 DOI: 10.1152/physrev.00034.2006]
136. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-E988 [PMID: 9374685]
137. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47: 530-537 [PMID: 9568683]
138. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JH, Ghatei MA, Bloom SR, Walters JR, Welbourn R, le Roux CW. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153: 3613-3619 [PMID: 22673227 DOI: 10.1210/en.2011-2145]
139. Adrian TE, Gariballa S, Parekh KA, Thomas SA, Saadi H, Al Kaabi J, Nagelkerke N, Gedulin B, Young AA. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 2012; 55: 2343-2347 [PMID: 22696033 DOI: 10.1007/s00125-012-2593-2]
140. Kitada Y, Kajita K, Taguchi K, Mori I, Yamauchi M, Ikeda T, Kawashima M, Asano M, Kajita T, Ishizuka T, Banno Y, Kojima I, Chun J, Kamata S, Ishii I, Morita H. Blockade of Sphingosine 1-Phosphate Receptor 2 Signaling Attenuates High-Fat Diet-Induced Adipocyte Hypertrophy and Systemic Glucose Intolerance in Mice. Endocrinology 2016; 157: 1839-1851 [PMID: 26943364 DOI: 10.1210/en.2015-1768]
141. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, Dent P. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell 2001; 12: 2629-2645 [PMID: 11553704]
142. Cummings BP, Bettaieb A, Graham JL, Kim J, Ma F, Shibata N, Stanhope KL, Giulivi C, Hansen F, Jelsing J, Vrang N, Kowala M, Chouinard ML, Haj FG, Havel PJ. Bile-acid-mediated decrease in endoplasmic reticulum stress: A potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech 2013; 6: 443-456 [PMID: 23264565 DOI: 10.1242/dmm.010421]
143. Cao AL, Wang L, Chen X, Wang YM, Guo HJ, Chu S, Liu C, Zhang XM, Peng W. Ursodeoxycholic acid and 4-phenylbutyrate prevent endoplasmic reticulum stress-induced podocyte apoptosis in diabetic nephropathy. Lab Invest 2016; 96: 610-622 [PMID: 26999661 DOI: 10.1038/labinvest.2016.44]
144. Kohli R, Setchell KD, Kirby M, Myronovych A, Ryan KK, Ibrahim SH, Berger J, Smith K, Toure M, Woods SC, Seeley RJ. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 2013; 154: 2341-2351 [PMID: 23592746 DOI: 10.1210/en.2012-2069]
145. Scholtz S, Miras AD, Chhina N, Prechtl CG, Sleeth ML, Daud NM, Ismail NA, Durighel G, Ahmed AR, Olbers T, Vincent RP, Alaghband-Zadeh J, Ghatei MA, Waldman AD, Frost GS, Bell JD, le Roux CW, Goldstone AP. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut 2014; 63: 891-902 [PMID: 23964100 DOI: 10.1136/gutjnl-2013-305008]
146. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H. Serum bile acid along with plasma incretins and serum highmolecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009; 58: 1400-1407 [PMID: 19570554 DOI: 10.1016/j.metabol.2009.05.006]
147. Steinert RE, Peterli R, Keller S, Meyer-Gerspach AC, Drewe J, Peters T, Beglinger C. Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. Obesity (Silver Spring) 2013; 21: E660-E668 [PMID: 23804517 DOI: 10.1002/oby.20522]
148. Belgaumkar AP, Vincent RP, Carswell KA, Hughes RD, Alaghband-Zadeh J, Mitry RR, le Roux CW, Patel AG. Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease. Obes Surg 2016; 26: 1195-1202 [PMID: 26337697 DOI: 10.1007/s11695-015-1878-1]
149. De Giorgi S, Campos V, Egli L, Toepel U, Carrel G, Cariou B, Rainteau D, Schneiter P, Tappy L, Giusti V. Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: A cross-sectional pilot study. Clin Nutr 2015; 34: 911-917 [PMID: 25306425 DOI: 10.1016/j.clnu.2014.09.018]
150. Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J, Strodel WE, Still CD, Argyropoulos G. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013; 36: 1859-1864 [PMID: 23801799 DOI: 10.2337/dc12-2255]
151. Jansen PL, van Werven J, Aarts E, Berends F, Janssen I, Stoker J, Schaap FG. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 2011; 29: 48-51 [PMID: 21691104 DOI: 10.1159/000324128]
152. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 2013; 37: 1553-1559 [PMID: 23567924 DOI: 10.1038/ijo.2013.38]
153. Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Käkelä P, Pääkkönen M, Hallikainen M, Kolehmainen M, Uusitupa M, Moilanen L, Laakso M, Gylling H, Patti ME, Auwerx J, Pihlajamäki J. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg 2012; 22: 1473-1480 [PMID: 22638681 DOI: 10.1007/s11695-012-0673-5]
154. Sachdev S, Wang Q, Billington C, Connett J, Ahmed L, Inabnet W, Chua S, Ikramuddin S, Korner J. FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes. Obes Surg 2016; 26: 957-965 [PMID: 26259981 DOI: 10.1007/s11695-015-1834-0]
155. Bhutta HY, Rajpal N, White W, Freudenberg JM, Liu Y, Way J, Rajpal D, Cooper DC, Young A, Tavakkoli A, Chen L. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLoS One 2015; 10: e0122273 [PMID: 25798945 DOI: 10.1371/journal.pone.0122273]
156. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, Kabaroglu C, Ozmen D, Mutaf I, Bayindir O. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011; 41: 390-396 [PMID: 22166511]
157. Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchies E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Bäckhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 2015; 6: 7629 [PMID: 26134028 DOI: 10.1038/ncomms8629]
158. Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am 2003; 32: 855-867 [PMID: 14711065]
159. Janikiewicz J, Hanzelka K, Kozinski K, Kolczynska K, Dobrzyn A. Islet β-cell failure in type 2 diabetes-Within the network of toxic lipids. Biochem Biophys Res Commun 2015; 460: 491-496 [PMID: 25843796 DOI: 10.1016/j.bbrc.2015.03.153]
160. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes-A convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342 [PMID: 11796484 DOI: 10.1210/endo.143.2.8623]
161. Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H, Wang MY, Unger RH, Sherry AD, Newgard CB. Biochemical mechanism of lipid-induced impairment of glucosestimulated insulin secretion and reversal with a malate analogue. J Biol Chem 2004; 279: 27263-27271 [PMID: 15073188 DOI: 10.1074/jbc.M401167200]
162. Carswell KA, Belgaumkar AP, Amiel SA, Patel AG. A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels. Obes Surg 2016; 26: 843-855 [PMID: 26210195 DOI: 10.1007/s11695-015-1829-x]
163. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: A time course study. Obes Surg 2005; 15: 474-481 [PMID: 15946424 DOI: 10.1381/0960892053723402]
164. Laferrère B. Do we really know why diabetes remits after gastric bypass surgery? Endocrine 2011; 40: 162-167 [PMID: 21853297 DOI: 10.1007/s12020-011-9514-x]
165. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes 2012; 61: 986-988 [PMID: 22517653 DOI: 10.2337/db11-1838]
166. Osto M, Abegg K, Bueter M, le Roux CW, Cani PD, Lutz TA. Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. Physiol Behav 2013; 119: 92-96 [PMID: 23770330 DOI: 10.1016/j.physbeh.2013.06.008]
167. Sledzinski T, Korczynska J, Hallmann A, Kaska L, Proczko-Markuszewska M, Stefaniak T, Sledzinski M, Swierczynski J. The increase of serum chemerin concentration is mainly associated with the increase of body mass index in obese, non-diabetic subjects. J Endocrinol Invest 2013; 36: 428-434 [PMID: 23211604 DOI: 10.3275/8770]
168. Zabrocka L, Raczynska S, Goyke E, Sledzinski Z, Swierczynski J. BMI is the main determinant of the circulating leptin in women after vertical banded gastroplasty. Obes Res 2004; 12: 505-512 [PMID: 15044668 DOI: 10.1038/oby.2004.57]
169. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes (Lond) 2008; 32 Suppl 7: S83-S92 [PMID: 19136997 DOI: 10.1038/ijo.2008.243]
170. Adami GF, Gradaschi R, Andraghetti G, Scopinaro N, Cordera R. Serum Leptin and Adiponectin Concentration in Type 2 Diabetes Patients in the Short and Long Term Following Biliopancreatic Diversion. Obes Surg 2016; 26: 2442-2448 [PMID: 26989058 DOI: 10.1007/s11695-016-2126-z]